OBJECTIVE: To examine trends in medical management of men with benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) in relation to sentinel events specific to particular medication regimens. METHODS: Using the National Ambulatory Medical Care Survey (1993-2010), we identified outpatient visits by men with BPH/LUTS. We ascertained prescriptions for medical therapy and distinguished between treatment with alpha-blocker monotherapy, 5α reductase inhibitor monotherapy, combination therapy, and anticholinergic therapy. We evaluated temporal trends in prescription patterns and assessed for changes after sentinel events related to each regimen (eg, Food and Drug Administration [FDA] approval for tamsulosin and alpha-blocker monotherapy). Finally, we used multivariable logistic regression to determine factors associated with each treatment strategy. RESULTS: From 1993 to 2010, there were over 101 million outpatient visits for men with a diagnosis of BPH/LUTS. Among these visits, the use of BPH medication increased from 14% of visits in 1993-1995 to over 40% of visits in 2008-2010 (P <.001). After tamsulosin was FDA approved, providers were twice as likely to prescribe ABs (odds ratio 2.35; 95% confidence interval 1.60-3.43). Providers were 5 times as likely to prescribe combination therapy after level 1 evidence supported its use (odds ratio 5.13; 95% confidence interval 3.35-7.86). CONCLUSION: Over the last 15 years, there has been a steady increase in the use of medications to manage men with BPH. Providers seem to have readily adopted novel medications and treatment regimens in response to FDA approval and supportive level 1 evidence.
OBJECTIVE: To examine trends in medical management of men with benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS) in relation to sentinel events specific to particular medication regimens. METHODS: Using the National Ambulatory Medical Care Survey (1993-2010), we identified outpatient visits by men with BPH/LUTS. We ascertained prescriptions for medical therapy and distinguished between treatment with alpha-blocker monotherapy, 5α reductase inhibitor monotherapy, combination therapy, and anticholinergic therapy. We evaluated temporal trends in prescription patterns and assessed for changes after sentinel events related to each regimen (eg, Food and Drug Administration [FDA] approval for tamsulosin and alpha-blocker monotherapy). Finally, we used multivariable logistic regression to determine factors associated with each treatment strategy. RESULTS: From 1993 to 2010, there were over 101 million outpatient visits for men with a diagnosis of BPH/LUTS. Among these visits, the use of BPH medication increased from 14% of visits in 1993-1995 to over 40% of visits in 2008-2010 (P <.001). After tamsulosin was FDA approved, providers were twice as likely to prescribe ABs (odds ratio 2.35; 95% confidence interval 1.60-3.43). Providers were 5 times as likely to prescribe combination therapy after level 1 evidence supported its use (odds ratio 5.13; 95% confidence interval 3.35-7.86). CONCLUSION: Over the last 15 years, there has been a steady increase in the use of medications to manage men with BPH. Providers seem to have readily adopted novel medications and treatment regimens in response to FDA approval and supportive level 1 evidence.
Authors: J Curtis Nickel; Peter Gilling; Teuvo L Tammela; Betsy Morrill; Timothy H Wilson; Roger S Rittmaster Journal: BJU Int Date: 2011-06-01 Impact factor: 5.588
Authors: Florian R Schroeck; John M Hollingsworth; Samuel R Kaufman; Brent K Hollenbeck; John T Wei Journal: J Urol Date: 2012-09-19 Impact factor: 7.450
Authors: Steven A Kaplan; Claus G Roehrborn; Eric S Rovner; Martin Carlsson; Tamara Bavendam; Zhonghong Guan Journal: JAMA Date: 2006-11-15 Impact factor: 56.272
Authors: Karim Chamie; Christopher S Saigal; Julie Lai; Jan M Hanley; Claude M Setodji; Badrinath R Konety; Mark S Litwin Journal: Cancer Date: 2011-07-11 Impact factor: 6.860
Authors: Emily C Chen; Rustom P Manecksha; Robert Abouassaly; Damien M Bolton; Oliver Reich; Nathan Lawrentschuk Journal: Prostate Int Date: 2014-12-30
Authors: Mohamed Bishr; Katharina Boehm; Vincent Trudeau; Zhe Tian; Paolo Dell'Oglio; Jonas Schiffmann; Claudio Jeldres; Maxine Sun; Sharokh F Shariat; Markus Graefen; Fred Saad; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2016 Jan-Feb Impact factor: 1.862
Authors: Micheal F Darson; Erik E Alexander; Zvi J Schiffman; Michael Lewitton; Robert A Light; Mark A Sutton; Carlos Delgado-Rodriguez; Ricardo R Gonzalez Journal: Res Rep Urol Date: 2017-08-21